Cerebrospinal fluid β(2)-microglobulin in patients with AIDS dementia complex: An expanded series including response to zidovudine treatment Journal Article

  

Authors:	Brew, B. J.; Bhalla, R. B.; Paul, M.; Sidtis, J. J.; Keilp, J. J.; Sadler, A. E.; Gallardo, H.; McArthur, J. C.; Schwartz, M. K.; Price, R. W.
Article Title:	Cerebrospinal fluid β(2)-microglobulin in patients with AIDS dementia complex: An expanded series including response to zidovudine treatment
Abstract:	Objective: To determine the relationship between cerebrospinal fluid (CSF) beta-2-Microglobulin (beta-2M) and severity of AIDS dementia complex (ADC), and between CSF beta-2M and response of ADC to zidovudine. Design: A prospective study. Setting. Tertiary referral hospital. Patients, participants: Seventy-eight patients with varying stages of ADC were selected from a subgroup of a cohort of HIV-seropositive patients who are being studied prospectively for the neurological complications of HIV-1 infection. To enter our study, patients had to have an ADC stage of at least 0.5 (equivocal symptoms or abnormal neurological signs in the absence of functional impairment). A control group of 11 HIV-1-seropositive, neurologically normal patients was chosen randomly from the patients followed in the Multicenter AIDS Cohort Study. Interventions: Patients were assessed neurologically and neuropsychologically and computed tomography of the brain and CSF studies were performed. Main outcome measures: Patients were staged according to severity of ADC on clinical criteria. Neuropsychological test scores were converted to an impairment score. CSF beta-2M was quantified in both serum and CSF of all patients and in 10 patients with pre- and post-zidovudine assessments. Results: There was a high correlation between CSF beta-2M concentration and severity of ADC (P < 0.0001); treatment with zidovudine significantly reduced these concentrations (P = 0.013). CSF beta-2M concentration was independent of CSF white-cell count and blood-brain barrier impairment. Other CSF changes in the same patients (including blood-brain barrier permeability to albumin, intrathecal synthesis of immunoglobulin G and HIV-1-p24-antigen levels) were less useful as objective correlates of ADC severity and response to zidovudine therapy. Conclusions: CSF beta-2M may be a valuable marker of ADC severity and response to antiviral therapy.
Keywords:	antigens; dementia; serum; igg; hiv-1; class-i; human-immunodeficiency-virus; hiv-1 infection; abnormalities; aids; blood-brain-barrier; beta-2-microglobulin; aids dementia complex; beta2-microglobulin
Journal Title:	AIDS
Volume:	6
Issue:	5
ISSN:	0269-9370
Publisher:	Lippincott Williams & Wilkins
Date Published:	1992-05-01
Start Page:	461
End Page:	465
Language:	English
ACCESSION:	WOS:A1992HT19700004
DOI:	10.1097/00002030-199205000-00004
PROVIDER:	wos
PUBMED:	1616651
Notes:	Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/152228